Enrico Rubboli ⚡

Building @mintlayer. Ex-Bitfinex/Tether. Bitcoin infrastructure, institutional adoption, and AI

[Enrico Rubboli ⚡ @dn2k]

On-chain transparency plus atomic settlement is not a crypto-native idea. It is a return to how institutional markets used to work before clearing became centralized. Mintlayer rebuilds that model for Bitcoin.

[Enrico Rubboli ⚡ @dn2k]

Most institutional venues hide three things: the real order book, how trades clear, and who holds the assets during settlement. Mintlayer removes all three by making the book on-chain and settlement atomic.

[Enrico Rubboli ⚡ @dn2k]

For firms evaluating Bitcoin-adjacent trading venues, the right question is not 'what is the liquidity?' It is 'what exactly am I trusting to settle my trade, and can I verify it independently?'

[Mintlayer @mintlayer]

📌 Save the Dates!

Catch our Co-founder @annamacmillan this week at @MENABCW!

🟦 20th May 2026
Panel: The New Payment Stack
📍 https://t.co/gyHSCnXD3n

🟦 21st May 2026
Panel: Built to Last: Security, Custody, and the Infrastructure Resilience Imperative
📍 https://t.co/p9S4a09cnv

🟦 22nd May 2026
Panel: Beyond the Buzz: Is There Real Institutional Demand for RWAs?
📍 https://t.co/CcTnNHBEtq

See you there!

[Anna MacMillan @annamacmillan]

Join us at @MENABCW 🎤

[Enrico Rubboli ⚡ @dn2k]

Reading The Martian by @andyweirauthor and I gotta ask... how's Mark duct-taping rovers back together on Mars while I'm over here losing my mind over an IKEA bookshelf? what brand is that tape Andy?? asking for me and my wobbly KALLAX 😭

[Enrico Rubboli ⚡ @dn2k]

Today it's 40 years of Internet in Italy. Back then I was playing with the observatory BBS in Ravenna, the only way I had to connect my computer with something else on a dial-up phone line.

[Mintlayer @mintlayer]

Join our “Bitcoin in the Quantum Age” Masterclass happening tomorrow!

⚡️Join @dn2k and @muurshb from @SeiNetwork for a deep dive into how quantum tech could impact Bitcoin, what risks are real (and when), and how to actually protect your BTC.

🔗 Register now before it’s full 👇
https://t.co/AiURTa8hx8

[Anna MacMillan @annamacmillan]

I think we should talk. We have put together a project running on our @mintlayer blockchain, for Real World Identity. Linking pet owners, to their pets in a traceable manner, to facilitate law enforcement on pet abandonment.
At the same time, our project allows the unification of pets health records, facilitating transfers from one clinic to the other, cross country and cross border. Minimizing quarantine requirements and etc
We are happy to share more and have already shared with the relevant UAE authorities, as we are happy to provide this on complimentary basis on a national level integration

[Enrico Rubboli ⚡ @dn2k]

Who said "plugins" ?

[Enrico Rubboli ⚡ @dn2k]

If you are building on @mintlayer using go, have a look at the new SDK https://t.co/H2MvXYuQHU

[Mintlayer @mintlayer]

Big moment for Bitcoin 👀

@dn2k Enrico Rubboli shares his perspective in @DecryptMedia on a proposal to freeze coins against quantum threats.

🔗Read the full piece: https://t.co/JTh4bDsPV0

[Dr. Jonathan N. Stea @jonathanstea]

Today is World Homeopathy Day.

In its honor, let’s remember that time The Amazing James Randi overdosed on homeopathy and lived to tell about it.

[Enrico Rubboli ⚡ @dn2k]

@FarvingCo https://t.co/nJAZV5y4Nl

[Enrico Rubboli ⚡ @dn2k]

BPC-157 has 30+ years of animal research showing tissue repair, anti-inflammation, neuroprotection. Human trials: basically zero. Why? No patent means no ROI for pharma to fund $100M+ trials. So nobody does it.

[Enrico Rubboli ⚡ @dn2k]

And the "protect people from themselves" argument? Alcohol kills 3 million people per year. Tobacco 8 million. Both legal, both heavily marketed. BPC-157 is non-addictive, no withdrawal, no receptor hijacking. Preclinical toxicology is clean. We permit documented mass scale harm but block compounds with unknown but preclinically safe profiles. That's not risk management. That's incoherence.

[Enrico Rubboli ⚡ @dn2k]

BPC-157 has 30+ years of animal research showing tissue repair, anti-inflammation, neuroprotection. Human trials: basically zero. Why? No patent means no ROI for pharma to fund $100M+ trials. So nobody does it.

[Enrico Rubboli ⚡ @dn2k]

The solution isn't banning the whole thing. Just regulate manufacturing quality. Require pharmaceutical grade purity and sterility. That addresses the actual stated safety concern without pretending we know the efficacy answer when we don't.